Sarah Gheuens - Feb 18, 2022 Form 4 Insider Report for AGIOS PHARMACEUTICALS, INC. (AGIO)

Role: Chief Medical Officer
Signature: /s/ William Cook, as attorney-in-fact for Sarah Gheuens
Stock symbol: AGIO
Transactions as of: Feb 18, 2022
Transactions value $: -$27,771
Form type: 4
Date filed: 2/23/2022, 03:12 PM
Previous filing: Feb 14, 2022
Next filing: Mar 3, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	AGIO	Common stock	Options Exercise	$0	+3.27K	+60%	$0.00	8.72K	Feb 18, 2022	Direct
transaction	AGIO	Common stock	Tax liability	-$27.8K	-955	-10.95%	$29.08	7.77K	Feb 22, 2022	Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	AGIO	Performance share units	Options Exercise	$0	-3.27K	-49.99%	$0.00	3.27K	Feb 18, 2022	Common stock	3.27K		Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each performance share unit represents a contingent right to receive one share of the issuer's common stock.
F2	The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.

Content

Each performance share unit represents a contingent right to receive one share of the issuer's common stock.

The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested.